Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009–2011

https://doi.org/10.1016/j.jdiacomp.2015.11.016Get rights and content
Under a Creative Commons license
open access

Abstract

Aims

Examine the association between obesity and glycemic control among patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM).

Methods

Data from US physician electronic health records (Humedica®) from 2009–2011 were utilized. Patients were defined as having above–target glycemic control if they had an HbA1c ≥ 7% at any time during the study period. Multinomial logistic regressions were conducted separately for T1DM and T2DM patients, and examined associations between BMI categories and probability of having above–target glycemic control (≥ 7% and < 8%, ≥ 8% and < 9%, or ≥ 9%) while controlling for patient demographics, general health, comorbid conditions, and antihyperglycemic medication use.

Results

There were 14,028 T1DM and 248,567 T2DM patients; 47.8% of T1DM and 63.4% of T2DM were obese (BMI ≥ 30 kg/m2). For T1DM, being overweight (BMI 25– < 30), obese class I (30– < 35), II (35– < 40), or III (≥ 40) was associated with a significantly higher probability of having HbA1c  8% and < 9% or ≥ 9%, while being overweight was associated with a significantly higher probability of having HbA1c ≥ 7% and < 8% compared to normal BMI (BMI  18.5 and < 25). For T2DM patients, being overweight, obese class I, II, or III was associated with a significantly higher probability of having HbA1c ≥ 7% and < 8%, ≥ 8% and < 9%, or ≥ 9%.

Conclusions

For both T1DM and T2DM patients, there were positive and statistically significant associations between being overweight or obese and having suboptimal glycemic control. These findings quantify the associations between obesity and glycemic control, and highlight the potential importance of individual characteristics on glycemic control.

Keywords

Obesity therapy
Glycemic control
Type 1 diabetes
Type 2 diabetes
Database research

Cited by (0)

Conflicts of Interest: Bae, Hoogwerf, Mo and Nelson completed this work as employees of Eli Lilly and Company, while Lage was compensated by Eli Lilly and Company for her work on this research.

1

Tel.: + 1 317 433 6572.

2

Tel.: + 1 317 209 5153.

3

Tel.: + 1 317 277 8032.

4

Tel.: + 1 317 292 6387.